Tumor Models Archives - Page 2 of 10

Isogeneic Trop-2 Model for Evaluating Anti-Trop-2 ADCs

Antibody-Drug Conjugates (ADCs) have made significant advancements in cancer treatment, particularly for solid tumors. The bystander effect of ADCs, where...

HPV18-Related Cancer Model Development

Cancers, like cervical cancer and head & neck cancer, are strongly linked to human papillomavirus (HPV) infection. Targeting the HPV...

AACR 2025 Posters: Sneak Peek

From April 25 to 30, 2025, the annual meeting of the American Association for Cancer Research (AACR), one of the...

Poster Presentations at AACR 2025

At this year’s annual meeting of the American Association for Cancer Research (AACR), WuXi Biology has been selected to present...

Synthetic Lethality Related Tumor Models

Synthetic lethality, where combining two non-lethal mutations results in cell death, is exploited in cancer therapy, with PARP inhibitors like...

Development, Characterization, and Therapeutic Utility of Paclitaxel-Resistant Models

Despite the excellent clinical response to paclitaxel therapy, drug resistance inevitably develops in subsequent treatments. The development of targeted therapies...

Therapeutic Potential of Polatuzumab Vedotin for the Treatment of DLBCL

Approximately 20-40% of diffuse large B-cell lymphoma (DLBCL) patients experience relapsed or refractory disease after initial treatment with R-CHOP (a...

Developing Resistant Models to Diverse ADC Drugs

Antibody‒drug conjugates (ADCs), which combine the advantages of monoclonal antibodies with precise targeting and payloads, show great potential as cancer...

Targeting FAK Improves the Tumor Uptake of ADCs

Antibody-drug conjugates (ADCs), exemplified by HER2-targeted Enhertu and TROP2-targeted Trodelvy, have demonstrated significant therapeutic potential in cancers. However, a subset...

Knowledge Library